Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized31P measurements of response to treatment

Autor: J. Glaholm, Timothy Andrew Davies Smith, Jonathan C. Sharp, Sabrina M. Ronen, M W Verrill, V. R. McCready, David J. Collins, Martin O. Leach, Geoffrey S. Payne, I. E. Smith, T. J. Powles
Rok vydání: 1998
Předmět:
Zdroj: NMR in Biomedicine. 11:314-340
ISSN: 1099-1492
0952-3480
DOI: 10.1002/(sici)1099-1492(1998110)11:7<314::aid-nbm522>3.0.co;2-z
Popis: A review of the literature has shown that in human breast tumours, large signals from phosphomonoesters (PME) and phosphodiesters (PDE) are evident. In serial measurements in 19 patients with breast cancer, a decrease in PME was significantly associated with a stable or responding disease (p = 0.017), and an increase in PME was associated with disease progression. Extract studies have shown PME to comprise of phosphoethanolamine (PEth) and phosphocholine (PCho), with the PEth to PCho ratio ranging from 1.3 to 12. The PCho content of high grade tumours was found to be higher than low grade tumours. In some animal models, changes in PCho have been shown to correlate with indices of cellular proliferation, and spheroid studies have shown a decrease in PCho content in spheroids with smaller growth fractions. A serial study of 25 patients with advanced primary breast tumours undergoing hormone, chemotherapy or radiotherapy treatments, showed that in this heterogenous group there were significant changes in metabolites that were seen during the first 3 weeks (range 2-4 weeks) of treatment, that correlated with volume change over this period, employed here as a measure of response. Changes in PME (p = 0.003), total phosphate (TP) (p = 0.008) and total nucleoside tri-phosphate (TNTP) (p = 0.02) over 3 (1) weeks were significantly associated with response, as were the levels of PME (p
Databáze: OpenAIRE
Externí odkaz: